

BIOLOGICS SAVINGS Partnership™



An innovative solution
to the rising cost of
drug-benefit plans

INTRODUCED BY



Biologics
Savings Partnership

CANADIAN DRUG PLAN SPENDING ON SPECIALTY DRUGS, INCLUDING BIOLOGICS, CONTINUES TO INCREASE^{1,2}

Biologic drugs are one of the fastest-growing market segments in the Canadian pharmaceutical industry³



BIOLOGIC DRUGS⁴

- Come from living organisms or from their cells
- Treat common diseases and medical conditions including anemia, diabetes, inflammatory bowel disease, psoriasis, rheumatoid arthritis, hormone deficiencies and some forms of cancer
- Biologic drugs are generally more complex than chemically produced pharmaceutical drugs



BIOSIMILAR DRUGS⁴

- Demonstrate high similarity to a brand name biologic that is already authorized for sale
- Are authorized based on a comparison to a brand name biologic and enter the market after the expiry of patents and data protection of their brand name biologic
- Are shown to be similar to their reference biologic but not identical due to the large size, complexity and natural variability of biologic drugs






SPECIALTY DRUGS*, including brand name biologics and biosimilars, **ACCOUNTED FOR 27% OF DRUG COSTS** on private plans in 2017²

*Defined as drugs costing >\$10,000 per year.

NOT ALL BRAND NAME BIOLOGICS AND BIOSIMILARS WORK IN THE SAME WAY

DID YOU KNOW...

-  The “**mechanism of action**” of a brand name biologic or biosimilar is what the drug does inside the body to treat a disease – in other words, how it works⁵
-  There are multiple “**classes**” of brand name biologics and biosimilars for chronic immunological diseases (e.g., plaque psoriasis, Crohn’s disease, ulcerative colitis, and rheumatoid arthritis)⁶
-  Each class is categorized by what the biologic treatments target within the body⁶


Some of the targets that brand name biologics and/or biosimilars may interact with include:⁷



Tumour necrosis factor alpha
(TNF α)



B cells
(Anti-CD20)



T cells
(T cell activation inhibitors/
co-stimulation modulators)






Interleukins
(IL-6, IL-12/23, IL-17,
and IL-23)

NOT ALL BRAND-NAME BIOLOGICS HAVE A CORRESPONDING BIOSIMILAR

CHRONIC IMMUNOLOGICAL DISEASES AND TREATMENT FAILURE

Chronic immunological diseases require treatment over an extended period of time. After a while, the brand name biologic or biosimilar treatment might stop working for a particular patient – this is called a “**treatment failure**”.⁸

Clinical trials have shown that a **substantial proportion of patients experience treatment failure**. This can result from patients:⁷

-  **Failing** to respond to treatment or having an inadequate response (called “primary failure”)
-  **Losing** response to treatment over time (called “secondary failure”)
-  **Developing** an adverse event

Treatment failure often results in patients switching to a different biologic therapy.⁹

For example, in rheumatoid arthritis, international treatment guidelines recommend that a new biologic therapy be considered after treatment failure, either from the same biologic class (i.e. the same target) or a different class (i.e. a new target) altogether.⁹



After treatment failure, patients may be **SWITCHED TO A BIOLOGIC TREATMENT OPTION** that has a **DIFFERENT TARGET**⁹



Patients may require **MULTIPLE BRAND NAME BIOLOGICS AND BIOSIMILARS** over the course of their disease

An innovative solution to the rising cost of drug-benefit plans

BIOLOGICALS ALONE MAY NOT BE THE ANSWER TO DRUG PLAN SUSTAINABILITY.

Given the chronic nature of inflammatory diseases, patients may require multiple biosimilar and/or brand name biologic therapies over time to treat their disease.^{8,10}

With the **BIOLOGICS SAVINGS PARTNERSHIP™**, **BRAND NAME BIOLOGICALS** are included at a **SIMILAR PRICE AS BIOSIMILARS**

Working with an insurance carrier that offers the **BIOLOGICS SAVINGS PARTNERSHIP™** presents an option to help with plan sustainability, delivering both **immediate- and long-term cost savings** for Plan Sponsors and their employees.

Along with potential savings from biosimilars, the **BIOLOGICS SAVINGS PARTNERSHIP™** enables **access to savings** across a breadth of **brand name biologics** in **different classes** and with **different targets**. This provides broader access to a range of biologic treatment options, including newer biologics, without an additional cost burden.



To complement savings from biosimilars, the **BIOLOGICS SAVINGS PARTNERSHIP™** includes brand name biologics that work against a variety of different targets

Introducing the

BIOLOGICS SAVINGS Partnership™



An innovative solution
to the rising cost of
drug-benefit plans



- Drug-benefit plans costs are being driven up by the **increasing number of claims** for innovative, specialty medicines – which include **biologics**^{2,10}
- People with chronic inflammatory diseases may require a number of different brand name biologics and/or biosimilars over the course of their disease^{8,9}
- Savings from **biosimilars alone may not be able to offset rising costs**¹⁰
- The **BIOLOGICS SAVINGS PARTNERSHIP™** provides access to a variety of **brand name biologics** at a **similar price as biosimilars**

Ask your Insurer if they have the
BIOLOGICS SAVINGS PARTNERSHIP™ agreement

References: 1. Canadian Institute for Health Information. *Prescribed Drug Spending in Canada, 2017: A Focus on Public Drug Programs*. Ottawa, ON: CIHI; 2017. 2. 2018 TELUS Health Drug Data Trends & National Benchmarks. 3. Canadian Institute for Health Information. *National Health Expenditure Trends, 1975 to 2017*. Ottawa, ON: CIHI; 2017. 4. Fact sheet: Biosimilars. Health Canada. Accessed August 2, 2018 at www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/fact-sheet-biosimilars.html. 5. Mechanism of action. *Segen's Medical Dictionary*. 2011. Farlex, Inc. Accessed August 7, 2018 at <https://medical-dictionary.thefreedictionary.com/mechanism+of+action>. 6. WebMD. *What are the different types of biologics?* Accessed August 1, 2018 at www.webmd.com/rheumatoid-arthritis/qa/what-are-the-different-types-of-biologics. 7. Strand V, et al. Immunogenicity of biologics in chronic inflammatory diseases: A systematic review. *BioDrugs* 2017;31:299–316. 8. Lin RJ. The biologic response to biologics. *Sci Transl Med* 2011;3(80):80ec61. Available at: <http://stm.sciencemag.org/content/3/80/80ec61>. Accessed July 9, 2018. 9. Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis* 2017;76:960–77. 10. Private Drug Plan Drug Cost Forecast (2016–2018): Research provided by QuintilesIMS for Innovative Medicines Canada. Innovative Medicines Canada. Available at: <http://innovativemedicines.ca/wp-content/uploads/2017/07/Private-Drug-Plan-Drug-Cost-Forecast-2016-2018.pdf>. Accessed July 17, 2018.

Janssen Inc. 19 Green Belt Drive | Toronto, Ontario | M3C 1L9 | www.janssen.com/canada
© 2019 Janssen Inc. | All trademarks used under license.

ACBR180616E

MEMBER OF
INNOVATIVE MEDICINES CANADA

janssen

BIOLOGICS SAVINGS Partnership™

